SYK Earnings Date: Feb 4, 2027 (Estimated) — Stryker Corporation
NYSE · Healthcare · Medical Devices
Updated
When is SYK's next earnings date?
Stryker Corporation (SYK) is expected to report Q4 2026 earnings on Thursday, February 4, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $5.13 on revenue of $7.98B.
How did SYK do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Stryker Corporation posted EPS of $3.52 versus the $3.55 estimate, a miss of 0.9%. Revenue was $6.52B against a $6.62B estimate.
How much does SYK stock move after earnings?
SYK beat EPS estimates in 6 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 3.8% (up or down) in the day after earnings.
About Stryker Corporation
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
🤖 AI Earnings Analysis
Stryker’s medical-device demand remains resilient, but Q3 was mixed: revenue rose 6.6% to $6.5B and EPS reached $3.52, both missing estimates amid operational headwinds. EPS guidance of $14.95–$15.10 offers support, but execution must improve.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | 3.55 | 3.52 | -0.85% | $6.52B | ❌ Miss | — | — | — |
| 2026-07-30 | Q2 2026 | 3.49 | 3.69 | +5.73% | $6.59B | ✅ Beat | -6.42% | -3.05% | -4.98% |
| 2026-04-30 | Q1 2026 | 2.98 | 2.60 | -12.75% | $6.02B | ❌ Miss | -6.47% | -6.63% | -4.97% |
| 2026-01-29 | Q4 2025 | 4.39 | 4.47 | +1.82% | $7.17B | ✅ Beat | +4.31% | +2.29% | +9.23% |
| 2025-10-30 | Q3 2025 | 3.14 | 3.19 | +1.59% | $6.06B | ✅ Beat | -3.45% | -4.11% | +0.91% |
| 2025-07-31 | Q2 2025 | 3.07 | 3.13 | +1.95% | $6.02B | ✅ Beat | -3.80% | -4.16% | -0.34% |
| 2025-05-01 | Q1 2025 | 2.70 | 2.84 | +5.19% | $5.87B | ✅ Beat | +1.13% | +2.26% | +1.84% |
| 2025-01-28 | Q4 2024 | 3.87 | 4.01 | +3.62% | $6.44B | ✅ Beat | -1.03% | -0.70% | -1.58% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $6.59B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| MedSurg | 55.0% | $3.63B | -3.9% | $4.18B | $3.51B | $3.77B | $3.80B |
| Orthopaedics | 45.0% | $2.96B | +31.7% | — | — | $2.25B | $2.25B |
By region
Q2 FY26 · $6.59B total
| Segment | Share | Revenue | YoY | Q2 FY24 | Q3 FY24 | Q1 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 75.3% | $4.96B | — | — | — | — | — |
| Non-US | 24.7% | $1.63B | +11.0% | $1.38B | $1.39B | $1.43B | $1.47B |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.